Structure of Chloroquine phosphate
CAS No.: 50-63-5
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. It is an autophagy and toll-like receptor (TLR) inhibitor and is highly effective in controlling SARS-CoV-2 (COVID-19) infection in vitro (EC50 = 1.13 μM).
Synonyms: Chloroquine(phosphate)(CRM); Chloroquine diphosphate; NSC 14050
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Perez, Celia N. ; Falcon, Cristian R. ; Mons, Johinna Delgado ; Orlandi, Federico Cuello ; Sangiacomo, Mercedes ; Fernandez-Munoz, Juan M. , et al.
Abstract: Over the last years, the incidence of melanoma, the deadliest form of skin cancer, has risen significantly. Nearly half of the melanoma patients exhibit the BRAFV600E mutation. Although the use of BRAF and MEK inhibitors (BRAFi and MEKi) showed an impressive success rate in melanoma patients, durability of response remains an issue because tumor quickly becomes resistant. Here, we generated and characterized Lu1205 and A375 melanoma cells resistant to vemurafenib (BRAFi). Resistant cells (Lu1205R and A375R) exhibit higher IC50 (5-6 fold increase) and phospho-ERK levels and 2-3 times reduced apoptosis than their sensitive parents (Lu1205S and A375S). Moreover, resistant cells are 2-3 times bigger, display a more elongated morphol. and have a modulation of migration capacity. Interestingly, pharmacol. inhibition of sphingosine kinases, that prevents sphingosine-1-phosphate production, reduces migration of Lu1205R cells by 50%. In addition, although Lu1205R cells showed increased basal levels of the autophagy markers LC3II and p62, they have decreased autophagosome degradation and autophagy flux. Remarkably, expression of Rab27A and Rab27B, which are involved in the release of extracellular vesicles are dramatically augmented in resistant cells (i.e. 5-7 fold increase). Indeed, conditioned media obtained from Lu1205R cells increased the resistance to vemurafenib of sensitive cells. Hence, these results support that resistance to vemurafenib modulates migration and the autophagic flux and may be transferred to nearby sensitive melanoma cells by factors that are released to the extracellular milieu by resistant cells.
Show More >
Keywords: Melanoma ; BRAF V600E mutation ; Vemurafenib ; Autophagy ; Resistance transfer
Show More >
| CAS No. : | 50-63-5 |
| Formula : | C18H32ClN3O8P2 |
| M.W : | 515.86 |
| SMILES Code : | CC(NC1=CC=NC2=CC(Cl)=CC=C12)CCCN(CC)CC.O=P(O)(O)O.O=P(O)(O)O |
| Synonyms : |
Chloroquine(phosphate)(CRM); Chloroquine diphosphate; NSC 14050
|
| MDL No. : | MFCD00069852 |
| InChI Key : | QKICWELGRMTQCR-UHFFFAOYSA-N |
| Pubchem ID : | 64927 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302 |
| Precautionary Statements: | P280-P305+P351+P338 |
In Vitro:
| Concentration | Treated Time | Description | References |
| HK-2 cells | 10 μM | 24 h | CQ remarkably reversed the nilotinib-induced decrease in MMP and inhibited nilotinib-induced intracellular ROS accumulation. | Adv Sci (Weinh). 2023 Sep;10(26):e2302002. |
| HUVECs | 10 μM | 24 h | CQ remarkably reversed the nilotinib-induced decrease in MMP and inhibited nilotinib-induced intracellular ROS accumulation. | Adv Sci (Weinh). 2023 Sep;10(26):e2302002. |
| WS hMSCs | 0.2-100 μM | Chloroquine at low concentrations (0.2-5 μM) promoted cell self-renewal, while higher concentrations (20 μM and above) inhibited cell proliferation. Treatment with 1 μM CQ decreased the percentage of SA-β-gal-positive cells and increased the number of Ki67-positive cells, while also reducing IL-6 secretion. | Protein Cell. 2022 Jun;13(6):454-461. | |
| U2OS cells | 10, 20, 40 μM | 16 h | Induced eIF2α phosphorylation | Cell Death Dis. 2021 Jan 6;12(1):6. |
| U2OS-GFP-LC3 ATG5 knockout cells | 10, 20, 40 μM | 6 h | ATG5 knockout cells failed to accumulate autophagosomes | Cell Death Dis. 2021 Jan 6;12(1):6. |
| U2OS-GFP-LC3 wild type cells | 10, 20, 40 μM | 6 h | Induced GFP-LC3 dot formation, indicating autophagosome accumulation | Cell Death Dis. 2021 Jan 6;12(1):6. |
| Human glioma H4 cells | 10, 20, 40 μM | 6 h | Induced GFP-LC3 dot formation, indicating autophagosome accumulation | Cell Death Dis. 2021 Jan 6;12(1):6. |
| Human U2OS osteosarcoma cells | 10, 20, 40 μM | 6 h | Induced GFP-LC3 dot formation, indicating autophagosome accumulation | Cell Death Dis. 2021 Jan 6;12(1):6. |
| lymphoblastoid cells | 100 μM | Chloroquine induced phosphorylation of KAP1 at S824 and ZEBRA expression, and the EBV lytic cycle reached completion, releasing substantial numbers of viral particles. | PLoS Pathog. 2017 Mar 1;13(3):e1006249. | |
| Jijoye and Raji Burkitt lymphoma cells | 200 μM | Chloroquine induced the expression of ZEBRA in both cell lines, although with different temporal patterns. | PLoS Pathog. 2017 Mar 1;13(3):e1006249. | |
| Calu-3 cells | 64.7 µM | Inhibit SARS-CoV-2 infection | J Mol Cell Biol. 2021 Jul 6;13(3):175-184. | |
| Vero E6 cells | 6.5 µM | Inhibit SARS-CoV-2 infection | J Mol Cell Biol. 2021 Jul 6;13(3):175-184. | |
| HH514-16 Burkitt lymphoma cells | 200 μM | 24 h | Chloroquine induced phosphorylation of KAP1 at S824 and activated the EBV lytic cycle. | PLoS Pathog. 2017 Mar 1;13(3):e1006249. |
| MiaPaca-2 | 100 μM | 72 h | To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ. | Biomacromolecules. 2017 Aug 14;18(8):2247-2257. |
| MiaPaca-1 | 100 μM | 72 h | To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ. | Biomacromolecules. 2017 Aug 14;18(8):2247-2257. |
| AsPC-1 | 100 μM | 72 h | To evaluate the cytotoxicity of CQ-HES, results showed that CQ-HES had similar cytotoxicity to HCQ. | Biomacromolecules. 2017 Aug 14;18(8):2247-2257. |
In Vivo:
| Administration | Dosage | Frequency | Description | References |
| C57BL/6J mice | Nilotinib-induced nephrotoxicity model | Oral | 30 mg/kg | Daily for 30 days | HCQ significantly reversed the nilotinib-induced elevation of BUN and Scr and ameliorated kidney cell apoptosis and oxidative stress induced by nilotinib. | Adv Sci (Weinh). 2023 Sep;10(26):e2302002. |
| Sprague Dawley (SD) rats | Physiologically aged rat model | Oral | 0.1 mg/kg | Twice a week for 5 months | Low-dose CQ treatment extended the lifespan of rats, repressed systemic inflammation, and inhibited fibrosis across multiple tissues. Furthermore, CQ treatment mitigated age-related molecular changes and repressed genes linked to fibrosis and the inflammatory response. | Protein Cell. 2022 Jun;13(6):454-461. |
| Mice | C57Bl/6j mice | Intraperitoneal injection | 50 mg/kg | Once daily for 10 days | Induced eIF2α phosphorylation | Cell Death Dis. 2021 Jan 6;12(1):6. |
| Mice | HCoV-OC43 infection model | 15 mg/kg | Prevent HCoV-OC43 infection | J Mol Cell Biol. 2021 Jul 6;13(3):175-184. |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT02563496 | Malaria, Vivax | Phase 2 | Recruiting | November 30, 2019 | Colombia ... More >> GSK Investigational Site Recruiting Monteria, Colombia Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Thailand GSK Investigational Site Not yet recruiting Tak, Thailand, 63110 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Vietnam GSK Investigational Site Recruiting Hanoi, Vietnam, 100000 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com GSK Investigational Site Recruiting Ho Chi Minh City, Vietnam, 700000 Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com GSK Investigational Site Recruiting Ho Chi Minh, Vietnam Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com Contact: EU GSK Clinical Trials Call Center +44 (0) 20 8990 4466 GSKClinicalSupportHD@gsk.com Less << |
| NCT01136850 | Malaria in Pregnancy ... More >> Sexually Transmitted Infections Anaemia Less << | Phase 3 | Completed | - | Papua New Guinea ... More >> Papua New Guinea Institute of Medical Research Madang, Madang Province, Papua New Guinea Less << |
| NCT00157859 | Falciparum Malaria ... More >> Vivax Malaria Less << | Not Applicable | Completed | - | Indonesia ... More >> SP9 & SP12 Public Health- Malaria control clinics Timika, Papua, Indonesia Less << |
| NCT01662700 | Acute Uncomplicated Malaria Wi... More >>th P.Vivax Infection Less << | Phase 4 | Unknown | December 2014 | Thailand ... More >> Kraburi Hospital Recruiting Ranong, Thailand Contact: Thongchai Keeratihatayagorn, MD +6681 8952244 Contact: Prakaykaew Charunwatthana, MD +6681-844 9678 jib@tropmedres.ac Sub-Investigator: Thongchai Keeratihatayagorn, MD Khunhan Hospital Recruiting Srisaket, Thailand Contact: Ratchadaporn Runchareon, MD +6681-790-9275 Contact: Prakaykaew Charunwatthana, MD +6681-844 9678 jib@tropmedres.ac Sub-Investigator: Ratchadaporn Runchareon, MD Phusing Hospital Recruiting Srisaket, Thailand Contact: Kitipumi Chutasmit, MD +6687 9654139 Contact: Prakaykaew Charunwatthan, MD +6681-844 9678 jib@tropmedres.ac Sub-Investigator: Kitipumi Chutasmit, MD Kap Choeng Hospital Recruiting Surin, Thailand Contact: Satawat Sinprasitkul, MD +6681 7601087 Contact: Prakaykaew Charunwatthana, MD +6681-844 9678 jib@tropmedres.ac Sub-Investigator: Satawat Sinprasitkul, MD Sub-Investigator: Worawun Kopkitngam, MD Less << |
| NCT02058173 | Hepatitis C Virus | Phase 4 | Completed | - | Iran, Islamic Republic of ... More >> Health Policy Research Center Shiraz, Fars, Iran, Islamic Republic of Less << |
| NCT01680406 | Plasmodium Vivax Infection | Phase 4 | Completed | - | Ethiopia ... More >> Bishoftu Malaria Center Debre Zeit, Ethiopia Batu Health Center Zeway, Ethiopia Less << |
| NCT01052584 | Malaria | Not Applicable | Completed | - | Ethiopia ... More >> DebreZeit Malaria Center Debrezeit, Oromia, Ethiopia Bulbula Health Center Zeway, Oromia, Ethiopia Less << |
| NCT02773979 | Plasmodium Falciparum Infectio... More >>n Less << | Phase 1 | Completed | - | United States, Washington ... More >> Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases Seattle, Washington, United States, 98101-1466 Less << |
| NCT00964691 | Malaria Malar... More >>ia in Pregnancy Less << | Phase 4 | Terminated(Low prevalence of m... More >>alaria, high prevalence of reported allergy to sulphur drugs, high proportion of women not meeting the inclusion criterea.) Less << | August 2010 | Solomon Islands ... More >> Honiara City Council Honiara, Solomon Islands Less << |
| NCT03337152 | Malaria, Vivax ... More >> G6PD Deficiency Less << | Phase 4 | Suspended(study met study halt... More >>ing rules) Less << | December 31, 2018 | Thailand ... More >> Shoklo Malaria Research Unit (SMRU) Mae Sot, Thailand Less << |
| NCT00399074 | Sickle Cell Anemia ... More >> Malaria Less << | Phase 3 | Completed | - | Uganda ... More >> Mulago Hospital Kampala, Central, Uganda, 256 Less << |
| NCT00084227 | Malaria, Falciparum | Phase 2 Phase 3 | Completed | - | - |
| NCT03400865 | Resistance, Disease ... More >> Prolactinoma Less << | Not Applicable | Not yet recruiting | December 30, 2020 | China, Beijing ... More >> Beijing Tiantan Hospital Not yet recruiting Beijing, Beijing, China China, Shanghai Huashan Hospital Not yet recruiting Shanghai, Shanghai, China, 200025 Ruijin Hosipital Enrolling by invitation Shanghai, Shanghai, China, 200025 China Chinese PLA General Hospital Not yet recruiting Beijing, China Peking Union Medical College Hospital Recruiting Beijing, China Xinqiao Hospital of Chongqing Not yet recruiting Chongqing, China First Affiliated Hospital of Fujian Medical Recruiting Fujian, China First Hospital of China Medical University Not yet recruiting Shenyang, China First Affiliated Hospital of Wenzhou Medical Univeristy Recruiting Wenzhou, China Less << |
| NCT00486694 | Malaria, Vivax | Phase 2 | Completed | - | - |
| NCT03243461 | Glioblastoma WHO Grade IV ... More >> Diffuse Midline Glioma Histone 3 K27M WHO Grade IV Anaplastic Astrocytoma WHO Grade III Diffuse Intrinsic Pontine Glioma Gliomatosis Cerebri Less << | Phase 3 | Recruiting | June 1, 2023 | Germany ... More >> Klinikum Augsburg Recruiting Augsburg, Germany Contact: Michael Frühwald, Prof. Evangelisches Krankenhaus Bielefeld Recruiting Bielefeld, Germany Contact: Norbert Jorch, Dr. Universitätsklinikum Bonn Recruiting Bonn, Germany Contact: Carola Weber, Dr. Klinikum Bremen-Mitte gGmbH Recruiting Bremen, Germany Contact: Arnulf Pekrun, Prof. Klinikum Chemnitz gGmbH Recruiting Chemnitz, Germany Contact: André Hofmann, Dr. Carl-Thiem-Klinikum Cottbus gGmbH Recruiting Cottbus, Germany Contact: Georg Schwabe, PD Dr. Sana Kliniken Duisburg GmbH - Wedau Kliniken Recruiting Duisburg, Germany Contact: Tanja Höll, Dr. Universitätsklinikum Erlangen Recruiting Erlangen, Germany Contact: Markus Metzler, Prof. Universitätsklinikum Freiburg Recruiting Freiburg, Germany Contact: Charlotte Niemeyer, Prof. Universitätsmedizin Greifswald Recruiting Greifswald, Germany Contact: Holger Lode, Prof. Universitätsmedizin Göttingen Recruiting Göttingen, Germany Contact: Christof Kramm, Prof. Universitätsklinikum Halle Recruiting Halle, Germany Contact: Toralf Bernig, Dr. Universitätsklinikum des Saarlandes Recruiting Homburg, Germany Contact: Norbert Graf, Prof. Gesundheit Nordhessen - Klinikum Kassel Recruiting Kassel, Germany Contact: Michaela Nathrath, Prof. Universitätsklinikum Leipzig Recruiting Leipzig, Germany Contact: Holger Christiansen, Prof. UMM Universitätsmedizin Mannheim Recruiting Mannheim, Germany Contact: Matthias Dürken, PD Dr. Johannes Wesling Klinikum Minden Recruiting Minden, Germany Contact: Bernhard Erdlenbruch, Prof. Universitätsklinikum Münster Recruiting Münster, Germany Contact: Ronald Sträter, PD Dr. Klinikum Oldenburg gGmbH Recruiting Oldenburg, Germany Contact: Hermann Müller, Prof. Universitätsklinikum Regensburg Recruiting Regensburg, Germany Contact: Marcus Jakob, Dr. ASKLEPIOS Klinik St. Augustin Recruiting Sankt Augustin, Germany Contact: Harald Reinhard, PD Dr. Klinikum Stuttgart - Olgahospital Recruiting Stuttgart, Germany Contact: Stefan Bielack, Prof. Universitätsklinikum Tübingen Recruiting Tübingen, Germany Contact: Martin Ebinger, PD Dr. Less << |
| NCT01728701 | Malaria Plasm... More >>odium Falciparum Less << | Phase 1 | Completed | - | Netherlands ... More >> Radboud University Nijmegen Medical Centre Nijmegen, Netherlands, 6500 HB Less << |
| NCT01783340 | Malaria, Falciparum | Phase 1 Phase 2 | Withdrawn(No funding) | April 2014 | Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2333ZA Less << |
| NCT03610399 | P Vivax Malar... More >>ia, Vivax Less << | Not Applicable | Recruiting | July 1, 2019 | Brazil ... More >> Hospital do Jurua Recruiting Cruzeiro do Sul, Brazil Contact: Suiane Negreiros, MD omsvalle@hotmail.com Principal Investigator: Suiane Negreiros, MD Less << |
| NCT01236612 | Plasmodium Falciparum Malaria | Not Applicable | Completed | - | Netherlands ... More >> Radboud University Nijmegen Medical Centre Nijmegen, Netherlands, 6500 HB Less << |
| NCT03208907 | Malaria, Vivax ... More >> Therapeutics Less << | Phase 3 | Not yet recruiting | December 2020 | - |
| NCT00084240 | Malaria, Falciparum | Phase 2 Phase 3 | Terminated(See Detailed Descri... More >>ption) Less << | - | - |
| NCT02394197 | Malaria | Phase 4 | Completed | - | - |
| NCT01218893 | Plasmodium Falciparum Malaria | Not Applicable | Completed | - | Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2300 RC Less << |
| NCT00132535 | Malaria in Pregnancy ... More >> HIV Infections Less << | Not Applicable | Completed | - | Uganda ... More >> Uganda AIDS Commission Kampala, Uganda, P.O. Box 10779 Less << |
| NCT01103063 | - | Terminated(See termination rea... More >>son in detailed description.) Less << | - | - | |
| NCT01103063 | Intermittent Preventive Treatm... More >>ent In Pregnancy (IPTp) Less << | Phase 3 | Terminated(See termination rea... More >>son in detailed description.) Less << | - | Benin ... More >> Centre de Santé d'AHOUANSORI-AGUE Cotonou, Benin Hôpital Bethesda Cotonou, Benin Kenya Siaya District Hospital Siaya, Kenya Malawi Zomba Central Hospital Zomba, Malawi Tanzania Teule Hospital Muheza, Tanga, Tanzania Bugando Medical Centre Mwanza, Tanzania, 1903 Nyamagana District Hospital, c/o National Institute for Medical Research, Mwanza Centre Mwanza, Tanzania Nyamagana District Hospital Mwanza, Tanzania Uganda Mulago Hospital Complex Kampala, Uganda Less << |
| NCT00082576 | Malaria, Falciparum | Phase 2 Phase 3 | Completed | - | Ghana ... More >> Pfizer Investigational Site Navrongo, Ghana Mali Pfizer Investigational Site Bamako, Mali Uganda Pfizer Investigational Site Jinja, Uganda Pfizer Investigational Site Kampala, Uganda Zambia Pfizer Investigational Site Ndola, Zambia Less << |
| NCT00455403 | Metabolic Syndrome X ... More >> Overweight Hypertension Dyslipidemias Prediabetic State Less << | Not Applicable | Active, not recruiting | December 2019 | United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less << |
| NCT00229775 | Malaria | Not Applicable | Completed | - | Philippines ... More >> Kalinga Health Center Tabuk, Kalinga Province, Philippines Davao Health Center Davao City, Mindinao, Philippines Palawan Health Center Puerto Princesa, Palawan, Philippines Less << |
| NCT02550964 | - | Recruiting | January 2019 | Korea, Republic of ... More >> Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Contact: JooYong Lee, Professor +82-2-3010-3976 ophthalmo@amc.seoul.kr Less << | |
| NCT00158548 | Malaria Falci... More >>parum Malaria Vivax Malaria Less << | Phase 3 | Completed | - | Pakistan ... More >> HealthNet International Peshawar, Pakistan Less << |
| NCT01446016 | Breast Neoplasms ... More >> Breast Cancer Less << | Phase 2 | Recruiting | August 1, 2019 | United States, Texas ... More >> Houston Methodist Hospital Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Cancer Center Research 713-441-0629 ccresearch@houstonmethodist.org Principal Investigator: Jenny Chang, MD Sub-Investigator: Angel A. Rodriguez, MD Sub-Investigator: Daniel Lehane, MD Sub-Investigator: Monisha Singh, MD Sub-Investigator: Tejal Patel, MD Sub-Investigator: Jorge Darcourt, MD Houston Methodist Hospital Willowbrook Recruiting Houston, Texas, United States, 77070 Contact: Houston Methodist Cancer Center 713-441-0629 ccresearch@houstonmethodist.org Principal Investigator: Anna Belcheva, MD Houston Methodist Hospital Sugar Land Recruiting Sugar Land, Texas, United States, 77479 Contact: Houston Methodist Cancer Center 713-441-0629 ccresearch@houstonmethodist.org Principal Investigator: Jorge Darcourt, MD Less << |
| NCT01422954 | Malaria Plasm... More >>odium Falciparum Less << | Not Applicable | Completed | - | Netherlands ... More >> Leiden University Medical Centre Leiden, Netherlands, 2333 ZA Less << |
| NCT00074841 | PLASMODIUM FALCIPARUM MALARIA | Phase 2 Phase 3 | Completed | - | India ... More >> Pfizer Investigational Site Dispur Guwahati, Assam, India, 781006 Pfizer Investigational Site Bambolim, Gao, India, 403002 Pfizer Investigational Site Nagpur, Maharashtra, India, 440 018 Pfizer Investigational Site Parel Mumbai, Maharashtra, India, 400012 Pfizer Investigational Site Rourkela, Orissa, India, 769005 Pfizer Investigational Site Vellore, Tamil Nadu, India, 632 004 Pfizer Investigational Site Indore, India, 452001 Less << |
| NCT01178021 | Vivax Malaria | Phase 4 | Unknown | December 2014 | Afghanistan ... More >> Provincial Malaria Control Centers (MRC) Recruiting Maimana, Faryab, Afghanistan Contact: Ghulam Rahim Awab, MD awabgr@yahoo.com Principal Investigator: Ghulam Rahim Awab, MD Provincial Malaria Control Centers (MRC) Recruiting Jalalabad, Afghanistan Contact: Ghulam Rahim Awab, MD Principal Investigator: Ghulam Rahim Awab, MD Provincial Malaria Control Centers (MRC) Recruiting Kunduz, Afghanistan Contact: Ghulam Rahim Awab, MD Principal Investigator: Ghulam Rahim Awab, MD Less << |
| NCT00137514 | Malaria, Falciparum | Phase 4 | Completed | - | Guinea-Bissau ... More >> Bandim Health Project Apartado 861, Bissau, Guinea-Bissau Less << |
| NCT00442403 | Malaria | Phase 3 | Suspended(At the end of the ye... More >>ar 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.) Less << | - | Cameroon ... More >> Institute of Medical Research and study of Medicinal Plants, Medical Research Center Yaounde, Cameroon Less << |
| NCT01378286 | Malaria | Phase 3 | Completed | - | Brazil ... More >> Administrative office Sao Paulo, Brazil Less << |
| NCT01366235 | Healthy Volunteers | Phase 1 | Completed | - | Korea, Republic of ... More >> Asan Medical Center Seoul, Korea, Republic of Less << |
| NCT01107145 | Plasmodium Vivax Malaria | Phase 4 | Terminated(Extremely slow enro... More >>llment) Less << | - | Brazil ... More >> Hospital Geral Maternidade de Cruzeiro do Sul Cruzeiro do Sul, Acre, Brazil Hospital Municipal Teonila Alves Anajas, Para, Brazil Centro de Pesquisa em Patologias Tropicais Porto Velho, Rondonia, Brazil Less << |
| NCT00391313 | Chikungunya Virus | Phase 3 | Terminated(Terminated Chikungu... More >>nya diseases has regressed and no more patients was suffering) Less << | - | France ... More >> Cellule Coordination Nivachik Saint Pierre, ile de la Reunion, France, 97400 Less << |
| NCT00677833 | - | Completed | - | - | |
| NCT01074905 | Vivax Malaria | Phase 3 | Completed | - | Thailand ... More >> Shoklo Malaria Research Unit Mae Sot, Thailand Less << |
| NCT00805519 | Osteoarthritis of the Knee | Phase 4 | Completed | - | Iran, Islamic Republic of ... More >> ArdabiUMS Clinic of Rheumatology Ardabil, Iran, Islamic Republic of, 56197 Less << |
| NCT00082563 | Malaria, Falciparum | Phase 2 | Terminated | - | - |
| NCT00677833 | Malaria, Falciparum | Phase 2 Phase 3 | Completed | - | Burkina Faso ... More >> Pfizer Investigational Site Nouna, Burkina Faso Pfizer Investigational Site Ouagadougou 01, Burkina Faso Pfizer Investigational Site Ouagadougou, Burkina Faso Côte D'Ivoire Pfizer Investigational Site Abidjan 13, Côte D'Ivoire Ghana Pfizer Investigational Site Navrongo, Ghana Kenya Pfizer Investigational Site Kisumu, Kenya, 40100 Mali Pfizer Investigational Site Bamako, West Africa, Mali Pfizer Investigational Site Sikasso, West Africa, Mali Less << |
| NCT00455325 | Metabolic Syndrome X ... More >> Overweight Hypertension Dyslipidemias Prediabetic State Less << | Phase 2 | Active, not recruiting | January 2019 | United States, Missouri ... More >> Washington University in St. Louis Saint Louis, Missouri, United States, 63110 Less << |
| NCT00290420 | Malaria | Phase 4 | Withdrawn(important delays and... More >> malaria season missed, due to political changes) Less << | November 2007 | - |
| NCT00125489 | Malaria Plasm... More >>odium Falciparum Malaria Less << | Phase 4 | Completed | - | Malawi ... More >> Blantyre Malaria Project Blantyre, Malawi Less << |
| NCT00849602 | Dengue | Phase 1 Phase 2 | Unknown | June 2009 | Brazil ... More >> São Paulo University Medical School at Ribeirão Preto Ribeirão Preto, SP, Brazil, 14048.900 Less << |
| NCT00224978 | Glioblastoma Multiforme | Phase 3 | Completed | - | Mexico ... More >> National Institute of Neurology and Neurosurgery Mexico City, Mexico, 14269 Less << |
| NCT00282919 | - | Completed | - | - | |
| NCT00379821 | Plasmodium Falciparum Infectio... More >>n Less << | Phase 3 | Completed | - | Malawi ... More >> Blantyre Malaria Project - Ndirande Health Centre Blantyre, Malawi Less << |
| NCT00282919 | Falciparum Malaria | Phase 2 | Completed | - | Colombia ... More >> Pfizer Investigational Site San Andres de Tumaco, Narino, Colombia India Pfizer Investigational Site Bambolim, Goa, India, 403002 Less << |
| NCT00426439 | Malaria, Falciparum | Phase 4 | Completed | - | Guinea-Bissau ... More >> Bandim Health Project Apartado 861, Bissau, Guinea-Bissau Less << |
| NCT00379821 | - | Completed | - | - | |
| NCT02043652 | - | Completed | - | - | |
| NCT03278808 | Malaria | Phase 2 | Recruiting | September 1, 2020 | United States, Maryland ... More >> Clinical Research Unit, Uniformed Services University of Health Sciences Not yet recruiting Bethesda, Maryland, United States, 20814 Contact: Thomas Oliver, MD 301-295-0016 thomas.g.oliver.mil@mail.mil WRAIR Recruiting Silver Spring, Maryland, United States, 20910 Contact: Jeffrey R Livezey, MD 301-319-3217 jeffrey.r.livezey.mil@mail.mil Less << |
| NCT00819390 | HIV Infections | Phase 2 | Completed | - | United States, Alabama ... More >> Alabama Therapeutics CRS (5801) Birmingham, Alabama, United States, 35294 United States, California Ucsd, Avrc Crs (701) San Diego, California, United States, 92103 United States, Colorado University of Colorado Hospital CRS (6101) Aurora, Colorado, United States, 80045 United States, District of Columbia Georgetown University CRS (GU CRS) (1008) Washington, District of Columbia, United States, 20007 United States, Maryland Johns Hopkins Adult AIDS CRS (201) Baltimore, Maryland, United States, 21205 United States, Massachusetts Massachusetts General Hospital ACTG CRS (101) Boston, Massachusetts, United States, 02114 United States, Missouri Washington University CRS (2101) St. Louis, Missouri, United States, 63110 United States, New York Cornell CRS (7804) New York, New York, United States, 10011 United States, North Carolina Unc Aids Crs (3201) Chapel Hill, North Carolina, United States, 27514 United States, Ohio Univ. of Cincinnati CRS (2401) Cincinnati, Ohio, United States, 45267 Case CRS (2501) Cleveland, Ohio, United States, 44106 MetroHealth CRS (2503) Cleveland, Ohio, United States, 44109 United States, Pennsylvania Hosp. of the Univ. of Pennsylvania CRS (6201) Philadelphia, Pennsylvania, United States, 19104 Pittsburgh CRS (1001) Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee Vanderbilt Therapeutics CRS (3652) Nashville, Tennessee, United States, 37204 Less << |
| NCT00323375 | Malaria | Phase 1 | Completed | - | United States, Louisiana ... More >> Tulane-LSU-Charity Hospital General Clinical Research Center New Orleans, Louisiana, United States, 70112 Less << |
| NCT01640574 | Vivax Malaria | Phase 3 | Completed | - | Thailand ... More >> Shoklo Malaria Research Unit Mae Sot, Tak, Thailand, 63110 Less << |
| NCT02043652 | Malaria | Not Applicable | Completed | - | Brazil ... More >> Hospital do Jurua Cruzeiro do Sul, Brazil Less << |
| NCT01218932 | Vivax Malaria | Phase 1 | Completed | - | Thailand ... More >> Hospital For Tropical Diseases Bangkok, Thailand Less << |
| NCT02348788 | Plasmodium Vivax Malaria Witho... More >>ut Complication Less << | Phase 3 | Recruiting | December 2017 | Malaysia ... More >> Kota Marudu District Hospital Recruiting Kota Marudu, Sabah, Malaysia Contact: Matthew Grigg, MBBS +60149569476 mat_grigg@hotmail.com Principal Investigator: Timothy William, MBBS Sub-Investigator: Tsin W Yeo, MBBS Sub-Investigator: Nicholas M Anstey, MBBS Sub-Investigator: Bridget E Barber, MBBS Sub-Investigator: Jayaram Menon, MBBS Sub-Investigator: Ric N Price, MBBS Sub-Investigator: Matthew J Grigg, MBBS Kudat District Hospital Recruiting Kudat, Sabah, Malaysia Contact: Matthew Grigg, MBBS +60149569476 mat_grigg@hotmail.com Sub-Investigator: Tsin W Yeo, MBBS Sub-Investigator: Nicholas M Anstey, MBBS Sub-Investigator: Bridget E Barber, MBBS Sub-Investigator: Prabakaran Dhanaraj, MBBS Sub-Investigator: Jayaram Menon, MBBS Sub-Investigator: Ric N Price, MBBS Principal Investigator: Timothy William, MBBS Sub-Investigator: Matthew J Grigg, MBBS Pitas District Hospital Recruiting Pitas, Sabah, Malaysia Contact: Matthew Grigg, MBBS +60149569476 mat_grigg@hotmail.com Principal Investigator: Timothy William, MBBS Sub-Investigator: Tsin W Yeo, MBBS Sub-Investigator: Nicholas M Anstey, MBBS Sub-Investigator: Bridget E Barber, MBBS Sub-Investigator: Jayaram Menon, MBBS Sub-Investigator: Ric N Price, MBBS Sub-Investigator: Matthew J Grigg, MBBS Less << |
| NCT00367653 | Malaria | Phase 3 | Completed | - | Burkina Faso ... More >> Pfizer Investigational Site Ouagadougou, West Africa, Burkina Faso, 01 Pfizer Investigational Site Nouna, Burkina Faso Ghana Pfizer Investigational Site Navrongo, West Africa, Ghana Kenya Pfizer Investigational Site Kisumu, Kenya, 40100 Mali Pfizer Investigational Site Bamako, West Africa, Mali Pfizer Investigational Site Bamako, Mali Senegal Pfizer Investigational Site Senegal, West Africa, Senegal Zambia Pfizer Investigational Site Ndola, Zambia Less << |
| NCT00819390 | - | Completed | - | - | |
| NCT02432417 | Glioblastoma ... More >>Astrocytoma, Grade IV Less << | Phase 2 | Not yet recruiting | January 2024 | - |
| NCT01443130 | Malaria | Phase 3 | Completed | - | Malawi ... More >> Blantyre Malaria Project - Queen Elizabeth Central Hospital Blantryre, Blantyre, Malawi Less << |
| NCT01019408 | Malaria, Falciparum | Phase 4 | Completed | - | Pakistan ... More >> Adezai Basic Health Unit Adezai, Nwfp, Pakistan Baghicha Basic Health Unit Baghicha, Nwfp, Pakistan Kagan Basic Health Unit Kagan, Nwfp, Pakistan Less << |
| NCT01438177 | Multiple Myeloma | Phase 2 | Terminated(PI left institution... More >>.) Less << | - | United States, New York ... More >> NYU Cancer Institute New York, New York, United States, 10016 Less << |
| NCT02192944 | Healthy | Phase 4 | Completed | - | Thailand ... More >> Faculty of Tropical Medicine, Mahidol University Bangkok, Thailand, 10400 Less << |
| NCT02333890 | Breast Cancer ... More >> Invasive Breast Cancer Less << | Phase 2 | Unknown | March 2018 | Canada, Ontario ... More >> The Ottawa Hospital Woman's Breast Health Centre Recruiting Ottawa, Ontario, Canada Contact: Angel Arnaout, Dr. 613-798-5555 Principal Investigator: Angel Arnaout, Dr. Less << |
| NCT01103713 | Asymptomatic Parasitemia In Pr... More >>egnancy Less << | Phase 3 | Terminated(See termination rea... More >>son in detailed description.) Less << | - | Benin ... More >> Centre de Sante d'AHOUANSORI -AGUE Cotonou, Benin Hôpital Bethesda Cotonou, Benin Kenya Siaya District Hospital Siaya, Kenya Malawi Zomba Central Hospital Zomba, Malawi Tanzania Teule Hospital Muheza, Tanga, Tanzania National Institute for Medical Research (Mwanza Centre)/ Nyamagana District Hospital Mwanza, Tanzania, 1903 Uganda Mulanda Health Centre IV Kampala, Uganda Less << |
| NCT01708876 | Uncomplicated Plasmodium Knowl... More >>esi Malaria Less << | Phase 3 | Completed | - | Malaysia ... More >> Kota Marudu District Hospital Kota Marudu, Sabah, Malaysia, 89108 Kudat District Hospital Kudat, Sabah, Malaysia, 89057 Pitas District Hospital Pitas, Sabah, Malaysia Less << |
| NCT01784315 | - | Unknown | December 2014 | Bhutan ... More >> Vector Diseases Control Program, Gelephu Not yet recruiting Gelephu, Bhutan, 00975 Contact: Dr.Yeshey Dorjey 97517745239 yesheydorjey@yahoo.com Contact: Dr.Kinley Penjor 97517619191 kalyx25@gmail.com Principal Investigator: Tobgyel Drukpa Sub-Investigator: Dr.Tashi Peldon Sub-Investigator: Dr.Kinley Penjor Vector Diseases Control Program, Gelephu Recruiting Gelephu, Bhutan, 00975 Contact: Dr.Yeshey Dorjey 97517745239 yesheydorjey@yahoo.com Contact: Dr.Kinley Penjor 97517619191 kalyx25@gmail.com Sub-Investigator: Tobgay Drukpa Sub-Investigator: Dr.Tashi Peldon Sub-Investigator: Dr.Kinley Penjor Mr. Thinly Recruiting Sarpang, Bhutan, 00975 Contact: Yeshey Dorjey, MBBS 008801534689426 yesheydorjey@yahoo.com Sub-Investigator: Dr. Kinly Penjor, MBBS Less << | |
| NCT01103713 | - | Terminated(See termination rea... More >>son in detailed description.) Less << | - | - | |
| NCT01650558 | HIV | Not Applicable | Active, not recruiting | March 2019 | Malawi ... More >> Blantyre Malaria Project Research Clinic Blantyre, Malawi Tisungane Clinic Zomba, Malawi Less << |
| NCT00473837 | Malaria Anaemia | Not Applicable | Completed | - | - |
| NCT01443130 | - | Completed | - | - | |
| NCT01438177 | - | Terminated(PI left institution... More >>.) Less << | - | - | |
| NCT00473837 | - | Completed | - | - | |
| NCT00871156 | Malaria | Phase 1 | Completed | - | United States, New York ... More >> GSK Investigational Site Buffalo, New York, United States, 14202 Less << |
| NCT00308620 | HIV Infections | Phase 2 Phase 3 | Terminated(Insufficient financ... More >>ial support; lack of efficacy for primary endpoint) Less << | - | United States, Minnesota ... More >> Minnesota ACTU Minneapolis, Minnesota, United States, 55455 Less << |
| NCT01100060 | Malaria Prophylaxis | Phase 1 | Completed | - | United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less << |
| NCT00308620 | - | Terminated(Insufficient financ... More >>ial support; lack of efficacy for primary endpoint) Less << | - | - | |
| NCT02118090 | Vivax Malaria | Phase 4 | Completed | - | Cambodia ... More >> Provincial Hospital Ban Lung, Rattanakiri, Cambodia Less << |
| NCT01078779 | Influenza | Phase 2 | Unknown | August 2010 | Singapore ... More >> Investigational Medicines Unit, National University Hospital Singapore, Singapore, 119074 Less << |
| NCT02001012 | Uncomplicated Knowlesi Malaria | Phase 3 | Completed | - | Malaysia ... More >> Kota Marudu District Hospital Kota Marudu, Sabah, Malaysia Kudat District Hospital Kudat, Sabah, Malaysia, 89057 Pitas District Hospital Pitas, Sabah, Malaysia Less << |
| NCT01777477 | Pancreatic Cancer | Phase 1 | Completed | - | Switzerland ... More >> University Hospital Zurich, Department of Oncology Zurich, ZH, Switzerland, 8091 Less << |
| NCT01727531 | Brain Metastasis | COMPLETED | 2025-08-13 | Lankenau Medical Center, Wynne... More >>wood, Pennsylvania, 19096, United States Less << | |
| NCT01785979 | Hyper-reactive Malarial Spleno... More >>megaly Malaria Anaemia Less << | Phase 3 | Withdrawn(Lack of funding) | February 2017 | Papua New Guinea ... More >> Lihir medical Centre Londolovit, New ireland province, Papua New Guinea Less << |
| NCT02378532 | Glioblastoma Multiforme | Phase 1 | Recruiting | June 2019 | Netherlands ... More >> Maastricht Radiation Oncology Recruiting Maastricht, Netherlands, 6202 AZ Less << |
| NCT00844207 | Malaria | Phase 1 | Completed | - | United States, Connecticut ... More >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511 Less << |
| NCT02932007 | Atrial Fibrillation | Phase 2 | Recruiting | September 2019 | United States, Florida ... More >> University of South Florida Recruiting Tampa, Florida, United States, 33606 Contact: Nhi Tran, MS 813-259-0628 nntran@health.usf.edu Contact: Jacob Siddoway jsiddoway@health.usf.edu Principal Investigator: Sami Noujaim, PhD Sub-Investigator: Bengt Herweg, MD Sub-Investigator: Dany Sayad, MD Less << |
| NCT00972725 | AIDS | Phase 2 | Completed | - | Belgium ... More >> GSK Investigational Site Gent, Belgium, 9000 Less << |
| NCT01716260 | - | Completed | - | Bhutan ... More >> Vector Diseases Control Program Gelephu, Bhutan Less << | |
| NCT02071537 | Malignant Neoplasm ... More >> Solid Tumors Less << | Phase 1 | Recruiting | December 2018 | United States, Ohio ... More >> University of Cincinnati Cancer Institute Recruiting Cincinnati, Ohio, United States, 45267-0502 Principal Investigator: Nagla Karim, MD, PhD Sub-Investigator: Johm Morris, MD Sub-Investigator: Sadia Benzaquin, MD Sub-Investigator: Pankaj Desai, MS, PhD Sub-Investigator: James Driscol, MD Sub-Investigator: Ahmed Khaled, MD Sub-Investigator: Jun Ying, PhD Less << |
| NCT01814423 | Malaria | Phase 4 | Completed | - | Guinea-Bissau ... More >> Projecto de Saúde de Bandim Bissau, Guinea-Bissau, 1004 Less << |
| NCT03687905 | - | Recruiting | September 30, 2019 | Egypt ... More >> Fatma Gheet Recruiting Tanta, Egypt Contact: Fatma S Gheet, M.B.,BCh +201148157993 fatmagheet@gmail.com Less << | |
| NCT02610686 | Plasmodium Vivax | Phase 4 | Unknown | December 2016 | Vietnam ... More >> Chu R Cam Recruiting Pleiku, Gia Lai, Vietnam Contact: Phuc Bui, MD, PhD +84 913522874 phucnimpe@yahoo.com Contact: Hong Nguyen, MD +84 01668188919 nvhong1982@yahoo.com Sub-Investigator: Annette Erhart, MD, PhD Sub-Investigator: Edu Rovira Vallbona, PhD Less << |
| NCT02004314 | HIV | Not Applicable | Completed | - | Canada, Quebec ... More >> Montreal Chest Institute, McGill University Health Centre Montreal, Quebec, Canada, H3A1A1 Less << |
| NCT01546961 | Vivax Malaria | Not Applicable | Active, not recruiting | September 2019 | Thailand ... More >> Shoklo Malaria Research Unit Tak, Mae Sot, Thailand, 63110 Less << |
| NCT02463331 | Autoimmune Hepatitis | Phase 4 | Completed | - | - |
| NCT02463331 | - | Completed | - | - | |
| NCT01023477 | Carcinoma, Intraductal, Noninf... More >>iltrating DCIS Ductal Carcinoma In Situ Less << | Phase 1 Phase 2 | Completed | - | United States, Virginia ... More >> Medical Oncology and Hematology Associates of Northern Virginia Fairfax, Virginia, United States, 22031 Virginia Cancer Specialists, PC Fairfax, Virginia, United States, 22031 Virginia Surgery Associates Fairfax, Virginia, United States, 22033 Inova Fairfax Hospital Falls Church, Virginia, United States, 22042 Less << |
| NCT00969306 | Small Cell Lung Cancer | Phase 1 | Completed | - | Netherlands ... More >> NKI/AvL Amsterdam, Netherlands VU Medical Center Amsterdam, Netherlands Maastricht Radiation Oncology Maastricht, Netherlands Maastricht University Medical Center Maastricht, Netherlands Less << |
| NCT00972725 | - | Completed | - | - | |
| NCT01575782 | Small Cell Lung Cancer | Phase 1 | Terminated(Poor accrual) | - | Netherlands ... More >> MAASTRO clinic Maastricht, Limburg, Netherlands, 6229 ET Less << |
| NCT02691910 | Malaria, Vivax | Phase 2 Phase 3 | Completed | - | Brazil ... More >> Oswaldo Cruz Foundation Rio de Janeiro, Brazil, 21040-360 Institute of Biomedical Sciences, University of Sao Paulo São Paulo, Brazil, 05508-900 Less << |
| NCT01894633 | Brain Metastasis | Phase 2 | Terminated(terminated) | - | Mexico ... More >> Instituto Nacional de Cancerologia Mexico DF, DF, Mexico, 14080 Less << |
| NCT01980745 | Hepatitis, Autoimmune | Phase 4 | Completed | - | Brazil ... More >> University of São Paulo School of Medicine Sao Paulo, Brazil, 05403-010 Less << |
| NCT02698748 | Malaria | Phase 2 Phase 3 | Completed | - | Mozambique ... More >> Centro de Investigaçao em Saude de Manhiça Manhiça, Maputo, Mozambique, 1902 Less << |
| NCT02496741 | Glioma Cholan... More >>giocarcinoma Chondrosarcoma Less << | Phase 1 Phase 2 | Unknown | December 2016 | Netherlands ... More >> VU University Medical Center Not yet recruiting Amsterdam, Noord-Holland, Netherlands, 1081 HZ Contact: Myra E Van Linde, M.D. +31(20)4441412 m.vanlinde@vumc.nl Academic Medical Center Recruiting Amsterdam, Noord-Holland, Netherlands, 1105AZ Contact: Hanneke W Wilmink, M.D., Ph.D. +31(20)5662895 j.w.wilmink@amc.uva.nl Contact: Remco J Molenaar, M.Sc. +31(20)5668587 r.j.molenaar@amc.nl Principal Investigator: Hanneke W Wilmink, M.D., Ph.D. Leiden University Medical Center Not yet recruiting Leiden, Zuid-Holland, Netherlands, 2333 ZA Contact: Hans J Gelderblom, M.D., Ph.D. +31(71)5269111 A.J.Gelderblom@lumc.nl Less << |
| NCT04323527 | SARS-CoV Infection|Severe Acut... More >>e Respiratory Syndrome (SARS) Pneumonia Less << | PHASE2 | COMPLETED | 2020-06-07 | Hospital e Pronto Socorro Delp... More >>hina Rinaldi Abdel Aziz, Manaus, Amazonas, 69093-415, Brazil Less << |
| NCT04328493 | SARS-CoV-2 Infection|COVID-19 | PHASE2 | COMPLETED | 2020-09-10 | National Hospital for Tropical... More >> Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam Less << |
| NCT04443270 | COVID-19 | PHASE1 | UNKNOWN | 2021-01-31 | Centro Médico Nacional "20 de ... More >>Noviembre", Mexico City, Benito Juárez, 03229, Mexico Less << |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.94mL 0.39mL 0.19mL |
9.69mL 1.94mL 0.97mL |
19.39mL 3.88mL 1.94mL |
|